Results 141 to 150 of about 46,913 (254)

Genome report: whole-genome assembly of the relapsing fever tick Ornithodoros turicata Dugès (Acari: Argasidae). [PDF]

open access: yesG3 (Bethesda)
Tietjen M   +10 more
europepmc   +1 more source

Checkpoint inhibitors, obinutuzumab plus PET‐adapted ultra‐low dose nodal radiotherapy yield high efficacy in treatment‐naïve follicular lymphoma: Results from the phase II ‘FLUORO’ study

open access: yesBritish Journal of Haematology, EarlyView.
Summary Follicular lymphoma (FL) first‐line chemoimmunotherapy yields high efficacy but serious toxicity in 65% of patients. In high tumour burden treatment‐naïve FL, we aimed to exploit known immunostimulatory and cytotoxic properties of combination checkpoint inhibition (atezolizumab) and obinutuzumab (6 cycles) with positron emission tomography (PET)
Arina Martynchyk   +15 more
wiley   +1 more source

Detection of Old and New World Relapsing Fever Borreliae in Ornithodoros Ticks Collected from Warthog Burrows in Zambia. [PDF]

open access: yesMicroorganisms, 2023
Qiu Y   +15 more
europepmc   +1 more source

Deciphering the full spectrum of Castleman diseases based on a cohort of 700 patients in a western country

open access: yesBritish Journal of Haematology, EarlyView.
The spectrum of Castleman diseases has expanded over the past three decades. The phenotype of the diseases varies not only among the three major types but also according to the patient ancestry. Summary Under the Castleman disease (CD) eponym, three distinct diseases sharing common pathological features have been described over time.
Eric Oksenhendler   +4 more
wiley   +1 more source

Ancient <i>Borrelia</i> genomes document the evolutionary history of louse-borne relapsing fever. [PDF]

open access: yesScience
Swali P   +31 more
europepmc   +1 more source

Real‐world treatment patterns and outcomes in accelerated and blast‐phase myeloproliferative neoplasms: Insights from a large multi‐centre cohort analysis in the United Kingdom

open access: yesBritish Journal of Haematology, EarlyView.
Summary This UK‐based retrospective analysis describes real‐world treatment patterns and outcomes in 175 patients with accelerated (AP, n = 69) or blast‐phase (BP, n = 106) ‘Philadelphia‐negative’ myeloproliferative neoplasms (MPN‐AP/BP) diagnosed between 2013 and 2025. Median age at transformation was 71 years.
Alexandros Rampotas   +35 more
wiley   +1 more source

Home - About - Disclaimer - Privacy